Across TCGA pan-cancer cohorts, ABCD3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ABCD3 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ABCD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABCD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
LUSC, COAD, and KIRP are the cancer types where ABCD3 Mutation most reproducibly stratifies survival.